Cargando…
Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis
Metastasis accounts for approximately 90% of breast cancer-related deaths. Therefore, novel approaches which prevent or control breast cancer metastases are of significant clinical interest. Interleukin-12 (IL-12)-based immunotherapies have shown promise in controlling metastatic disease, yet modest...
Autores principales: | Vo, Jimmy LN, Yang, Lirong, Kurtz, Samantha L, Smith, Sean G, Koppolu, Bhanu prasanth, Ravindranathan, Sruthi, Zaharoff, David A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352958/ https://www.ncbi.nlm.nih.gov/pubmed/25964864 http://dx.doi.org/10.4161/21624011.2014.968001 |
Ejemplares similares
-
Immunological mechanisms of intravesical chitosan/interleukin-12 immunotherapy against murine bladder cancer
por: Smith, Sean G., et al.
Publicado: (2016) -
Effect of Chitosan Properties on Immunoreactivity
por: Ravindranathan, Sruthi, et al.
Publicado: (2016) -
Tumor-derived granulocyte colony-stimulating factor diminishes efficacy of breast tumor cell vaccines
por: Ravindranathan, Sruthi, et al.
Publicado: (2018) -
Modulation of Interleukin-12 activity in the presence of heparin
por: Jayanthi, Srinivas, et al.
Publicado: (2017) -
Localized Interleukin-12 for Cancer Immunotherapy
por: Nguyen, Khue G., et al.
Publicado: (2020)